How long can rubitin/rubicatin (Zanbiga) prolong patients' lifespan and analysis of its efficacy

Lurbinectedin (also known as rubicatin) is a new type of DNA binding anti-tumor drug, mainly used to treat small cell lung cancer (SCLC) and some solid tumors. Its mechanism of action is to block tumor cell proliferation and induce cancer cell apoptosis by binding to the minor groove of DNA and inhibiting the transcription process. In addition, rubitin can also inhibit the immunosuppressive effect of tumor-associated macrophages, thereby improving the tumor microenvironment and having dual effects on tumor control.

Clinical studies have shown that rubitidine has significant efficacy in patients with recurrent small cell lung cancer. In patients who relapse after prior platinum-based chemotherapy, monotherapy can achieve a median progression-free survival (PFS) of approximately 3 months, the median overall survival (OS) is about 9.3 months, and some patients can achieve partial tumor response or stable status. Compared with traditional chemotherapy, rubitidine provides new survival benefits in relapsed and refractory patients and is clinically considered a feasible second-line treatment option.

The efficacy of rubitin is characterized by rapid onset of action and still a certain control effect on drug-resistant patients. Patients generally report that the tumor burden has decreased during treatment, and some symptoms such as dyspnea and fatigue have been relieved, thereby improving the quality of life. It was generally well tolerated, with common adverse reactions including hematological toxicity (neutropenia, anemia), fatigue, nausea, and mild liver function abnormalities. Most adverse reactions can be controlled through dose adjustment or supportive care.

Rubitidine provides an important treatment option for patients with recurrent small cell lung cancer and some solid tumors, especially for patients who are relapsed or refractory to platinum-based chemotherapy. Although the efficacy of a single agent is limited, the therapeutic effect can be further enhanced through combination chemotherapy or immunotherapy. In the future, as more clinical trial data accumulate, rubitidine is expected to play a greater role in improving patient survival and quality of life, providing a reliable clinical strategy for refractory tumors.

Reference materials:https://www.drugs.com/